LUMASIRAN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lumasiran sodium and what is the scope of patent protection?
Lumasiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lumasiran sodium has one hundred and seventy-four patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for LUMASIRAN SODIUM
| International Patents: | 174 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | LUMASIRAN SODIUM at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUMASIRAN SODIUM
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for LUMASIRAN SODIUM
US Patents and Regulatory Information for LUMASIRAN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LUMASIRAN SODIUM
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 4039809 | COMPOSITIONS ET MÉTHODES D'INHIBITION DE L'EXPRESSION GÉNIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION) | ⤷ Sign Up |
| New Zealand | 730296 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2016057893 | ⤷ Sign Up | |
| European Patent Office | 4321177 | CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUMASIRAN SODIUM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3581654 | 2021038 | Norway | ⤷ Sign Up | PRODUCT NAME: LUMASIRAN; REG. NO/DATE: EU/1/20/1496 20201124 |
| 3581654 | SPC/GB21/059 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LUMASIRAN; REGISTERED: UK EU 1/20/1496 (NI) 20201123; UK PLGB 50597/0005 20201123 |
| 3581654 | C20210019 00342 | Estonia | ⤷ Sign Up | PRODUCT NAME: LUMASIRAAN;REG NO/DATE: EU/1/20/1496 23.11.2020 |
| 3581654 | C03581654/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: LUMASIRANUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68239 01.12.2021 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
